[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aki---acute-kidney-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aki---acute-kidney-injury":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,45,75,111,137,164,198,220,251,274,297,318,343,370,392,420,449,474,496,519,542,563,586],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100641363","phase-2-efficacy-and-safety-of-sp16-in-preventing-acute-kidney-injury-in-at-risk-subjects-with-chronic-kidney-disease-undergoing-elective-cardiac-surgery-using-the-heart-lung-machine-100641363",false,"NCT07661940","Efficacy and Safety of SP16 in Preventing Acute Kidney Injury in At-risk Subjects With Chronic Kidney Disease Undergoing Elective Cardiac Surgery Using the Heart-lung-machine","Efficacy and Safety of SP16 in Preventing Acute Kidney Injury in At-risk Subjects With Chronic Kidney Disease Undergoing Elective Cardiac Surgery Using the Heart-lung-machine: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial (EASE-AKI)","EASE-AKI","Inclusion Criteria:\n\n* Individual aged ≥18 years.\n* Male or female.\n* Scheduled for CABG OR aortic valve surgery (aortic valve replacement or repair alone, with or without aortic root repair) OR mitral valve surgery OR aortic\u002Fmitral valve surgery combined with CABG.\n* Use of the CPB during surgical intervention expected.\n* Written informed consent obtained from the participant.\n* Understanding of study procedures and willingness to abide by all procedures during the course of the clinical trial.\n* CKD Stage 2-3b with eGFR ≤90 and ≥30 ml\u002Fmin\u002F1.73 m2 (according to 2021 CKD-EPI equation) known for ≥ 3 months prior to enrollment\n* BMI ≥19 kg\u002Fm² to ≤40 kg\u002Fm².\n* Contraceptive measures:\n\nFemale participants must fulfil at least one of the following criteria of highly effective contraception (according to CTFG recommendations v1.2) during and up to 3 months after the end of study participation:\n\n* Menopause (at least 12 months of natural amenorrhoea or 6 months of amenorrhoea with serum FSH \\>40 mU\u002Fml) OR\n* Condition after bilateral ovariectomy or hysterectomy for at least 6 weeks prior to the screening appointment (Visit 1a, Day 54 to -2) OR\n* Regular, correct and reliable use of a contraceptive method with an error rate ≤1% per year:\n\n  1. Inhibition of ovulation by estrogen and progesterone combination preparations (oral, intravaginal, or transdermal) or\n  2. Inhibition of ovulation by progesterone monopreparations (oral, per injectionem \\[depot injections\\], or implant) or\n  3. Intrauterine device, hormone coil OR\n* Bilateral tubal ligation OR\n* Vasectomy of all partners OR\n* Sexual abstinence.\n\nMale participants must fulfill at least one of the following contraceptive criteria during and up to 3 months after the end of participation in the study:\n\n* Vasectomy OR\n* Regular, correct, and reliable use of condoms\n\nExclusion Criteria:\n\n* CKD stages 4-5 with eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m2 pre-surgery as determined by CKD EPI.\n* Previous cardiac surgery.\n* Person has a kidney transplant or another solid organ transplant.\n* Person is scheduled for intermittent or continuous renal replacement therapy (dialysis).\n* Known diagnosis of dementia or other clinical signs of mental illness that will prevent full understanding.\n* Known diagnosis of severe COPD (Gold 3) and\u002For FEV1 \\\u003C 1 l\u002Fs.\n* Heart failure with severity of symptoms according to NYHA IV.\n* Heart failure with impaired cardiac pump function (LVEF \\\u003C35%).\n* Acute onset or ongoing sepsis - sepsis is defined as the presence of a confirmed or putative infection, along with a dysregulated systemic immune reaction leading to organ dysfunction.\n* Clinical signs of a currently active infection including endocarditis requiring antibiotic treatment.\n* Clinical signs of an acute viral infection.\n* Serious underlying disease(s) or very poor general medical condition, so that in the investigator's judgment the person is not expected to survive ICU or hospital stay.\n* Patient who has an active (requiring treatment) malignancy or history within 5 years prior to enrollment in the study, of solid, metastatic or hematologic malignancy with the exception of basal or squamous cell carcinoma of the skin that has been removed.\n* Administration of iodinated contrast agent within 24 hours prior to cardiac surgery\n* Recent (discontinued in the last 14 days before V1a or V1b) or current treatment with immunosuppressive drugs, including, but not limited to, high dose corticosteroids \\[\\> 1 mg\u002Fkg of prednisone equivalent\\], tumour necrosis factor alpha blockers, or ciclosporin.\n* Current regular use of anti inflammatory drugs such as NSAID, with discontinuation not possible. (however, if these medications are discontinued in the last 10 days before V2, the participant is eligible to participate). ASA up to 100 mg per day is allowed.\n* Systemic corticosteroid therapy (any dose).\n* Known active chronic inflammatory disease (including, but not limited to, rheumatoid arthritis or systemic lupus erythematosus).\n* Known allergy to SP16 or to other ingredients of the IMP.\n* Person who is not willing to use highly effective contraceptive measures (according to CTFG recommendations v1.2).\n* Pregnant women.\n* Breastfeeding women.\n* Current participation in another interventional clinical study (register studies or non-interventional, observational studies excluded).\n* Employee or direct relative of an employee of the study site, the CRO, or the Sponsor.","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This clinical study investigates the safety and potential effectiveness of the investigational drug SP16 in preventing acute kidney injury in patients with pre-existing chronic kidney disease who are undergoing cardiac surgery involving the use of cardiopulmonary bypass (heart-lung machine).\n\nSP16 is an investigational medicinal product that has not yet been approved for clinical use. To date, it has been studied in 28 individuals. The sponsor aims to evaluate whether SP16 can safely reduce or prevent kidney damage associated with the inflammatory and ischemia-reperfusion processes that may occur during cardiac surgery with cardiopulmonary bypass.\n\nParticipation in the study extends over a period of slightly more than five months. Screening procedures are performed within approximately seven weeks to two days before the scheduled surgery to determine eligibility for participation. During the hospitalization for cardiac surgery, which is expected to last approximately 10 days, a total of 11 study visits are conducted. Follow-up assessments include a telephone contact approximately one month after hospital discharge and a final on-site study visit approximately three months after discharge.\n\nThis is a randomized, double-blind, placebo-controlled clinical trial. Participants are randomly assigned to receive either SP16 or a placebo, which contains no active ingredient. Neither the participants nor the investigators know which treatment has been assigned during the study period.\n\nBased on previous preclinical and early clinical findings, SP16 may have the potential to reduce or mitigate kidney injury caused by the use of the heart-lung machine during cardiac surgery. However, since the efficacy of SP16 has not yet been proven, no clinical benefit can be guaranteed. Participants receiving placebo are not expected to derive a direct therapeutic benefit from study treatment.",[27],"AKI - Acute Kidney Injury",[29,30,31],"AKI","cardiac surgery","CKD","NOT_YET_RECRUITING","2026-06-22",{"date":35,"type":36},"2026-06-25","ACTUAL",{"date":38,"type":21},"2026-06-18",{"date":40,"type":21},"2029-05",{"name":42,"class":43},"University of Erlangen-Nürnberg Medical School","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100559457","tailored-mgso4-supplementation-to-reduce-complications-in-pediatric-heart-surgery-100559457","NCT06564376","Tailored MgSO4 Supplementation to Reduce Complications in Pediatric Heart Surgery","Individually Tailored MgSo4 Supplementation to Reduce Cardiac and Renal Complications in Pediatric Heart Surgery","Inclusion Criteria:\n\n* Children undergoing cardiac surgery utilizing cardiopulmonary bypass\n\nExclusion Criteria:\n\n* Children undergoing cardiac surgery without cardiopulmonary bypass\n* Children with Renal disease\n* Children with pre-existing arrhythmia\n* Children on anti-arrhythmia medication","0 Years",{"count":54,"type":21},96,[56],"NA","Lay Summary\n\nThis study tests two ways of measuring blood magnesium after heart surgery. Children who need heart surgery may have heart and kidney problems after surgery. The right amount of magnesium in blood reduces this risk. This study will test the best way to measure magnesium. This will let doctors choose the right dose of MgSO4. MgSO4 is a magnesium supplement. Taking MgSO4 after heart surgery helps children. For each child, it is best to personalize MgSO4 dose. This is based on the amount of magnesium in blood. This study will test two ways of personalizing MgSO4 dose.\n\nIn the blood, there are two kinds of magnesium. Usually, blood magnesium tests measure both forms together. This does not say anything about active magnesium. This study will measure the two forms separately. Then, MgSO4 will be given based on either the active or whole magnesium. Measuring active magnesium is good. Active magnesium levels change faster than total. That means active magnesium tests may better protect children. Also, active magnesium has more of an impact on heart and kidney function. Focusing on the active form will help these organs stay healthy.\n\nTo test how well the MgSO4 is working, heart and kidneys will be examined. After surgery, certain harmful heart rhythms can occur. The types and number of harmful rhythms will be studied. Kidney problems can also happen after heart surgery. Kidney health will be studied. To help understand how active magnesium works, further tests will be done. These tests will look for evidence of poor health in the cells that make up the heart, kidney, and blood.",[27,59,60],"Arrythmia","Congenital Heart Disease",[62,63,64,65],"Acute Kidney Injury","Arrhythmias","Congenital heart surgery","Cardiopulmonary bypass","2026-06-12",{"date":68,"type":36},"2026-06-16",{"date":70,"type":21},"2026-08-01",{"date":72,"type":21},"2029-06",{"name":74,"class":43},"West Virginia University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":44},"100640008","phase-4-rhbnp-for-prevention-of-cardiac-surgery-associated-acute-kidney-injury-csa-aki-100640008","NCT07617675","rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)","Perioperative Recombinant Human Brain Natriuretic Peptide for Renal Protection in Cardiac Surgery: the PROTECT-CS Randomized Clinical Trial","PROTECT-CS","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Scheduled (elective) cardiac surgery requiring cardiopulmonary bypass\n* Presence of at least one of the following AKI risk factors:\n* Age ≥ 70 years\n* Preoperative renal impairment (eGFR ≤ 60 mL\u002Fmin\u002F1.73 m² or urine protein ≥ +2 at screening)\n* Type 2 diabetes mellitus\n* Heart failure, defined as NYHA Class II-IV with NT-proBNP ≥ 125 pg\u002FmL at screening; for participants with atrial fibrillation, NT-proBNP ≥ 365 pg\u002FmL is required\n* Able to understand and provide written informed consent, and willing and able to comply with all study protocol requirements\n\nExclusion Criteria:\n\n* Cardiogenic shock\n* Severe hypotension (systolic blood pressure ≤ 90 mmHg) at screening\n* Restrictive or obstructive cardiomyopathy, pericarditis, or cardiac tamponade\n* Preoperative chronic kidney disease stage 4 or higher (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²), or renal instability as judged by the investigator\n* Known AKI diagnosed per KDIGO criteria within 48 hours prior to surgery\n* Receipt of any form of renal replacement therapy within 30 days prior to surgery\n* Use of ventricular assist device, intra-aortic balloon pump, or any other mechanical cardiac support device within 7 days prior to surgery\n* Chronic hepatic insufficiency (Child-Pugh Class B or C) or hepatic dysfunction (ALT or AST \\> 2× upper limit of normal \\[ULN\\], or total bilirubin \\> 1.5× ULN)\n* Active hepatitis B (HBsAg positive with HBV-DNA indicating active viral replication), active hepatitis C (HCV antibody positive with HCV-RNA indicating active viral replication), positive syphilis screen, known HIV infection, or positive HIV test\n* Confirmed or treated endocarditis, sepsis, or active infection requiring antibiotic treatment within 30 days prior to surgery\n* Requirement for aortic dissection repair, complex congenital heart surgery, emergency surgery, or life-saving surgery\n* History of malignant tumor, solid tumor, metastatic tumor, or hematological malignancy within the past 5 years\n* Prior organ transplantation or current use of immunosuppressive agents\n* Any condition that may conflict with or contraindicate the use of intravenous vasodilator therapy\n* Prior adverse reaction to nesiritide (recombinant BNP)\n* Participation in any other clinical trial within 30 days prior to surgery\n* Pregnant or breastfeeding women\n* Any other condition that, in the judgment of the investigator, renders the participant unsuitable for study participation",{"count":84,"type":21},694,[86],"PHASE4","Cardiac surgery-associated acute kidney injury (CSA-AKI) is a common and serious perioperative complication, independently associated with prolonged hospitalization, increased mortality, and progression to chronic kidney disease. Despite advances in surgical techniques and postoperative care, no widely accepted pharmacological prevention strategy exists.\n\nRecombinant human brain natriuretic peptide (rhBNP) exerts vasodilatory, diuretic, and natriuretic effects, reduces cardiac preload and afterload, and has demonstrated safety and efficacy in treating congestive heart failure. Preliminary studies suggest rhBNP may reduce postoperative serum creatinine, increase urine output, and improve renal outcomes; however, large-scale randomized controlled evidence is lacking.\n\nThe PROTECT-CS trial is a multicenter, prospective, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of perioperative continuous intravenous rhBNP infusion (0.01 μg\u002Fkg\u002Fmin for 48 ± 2 hours) for prevention of AKI in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass. A total of 694 participants will be enrolled across 7 centers in China.",[27,89,90],"Cardiac Surgical Procedures","Cardiopulmonary Bypass",[92,93,94,95,96,65,97,98,99,100],"Recombinant human brain natriuretic peptide","rhBNP","Nesiritide","Acute kidney injury","Cardiac surgery","Renal protection","Randomized controlled trial","Cardiac surgery-associated acute kidney injury","CSA-AKI","2026-05-29",{"date":103,"type":36},"2026-06-01",{"date":105,"type":21},"2026-05-01",{"date":107,"type":21},"2029-07-31",{"name":109,"class":110},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100639416","continuous-renal-replacement-therapy-impact-on-intensive-care-unit-length-of-stay-100639416","NCT07586059","Continuous Renal Replacement Therapy, Impact on Intensive Care Unit Length of Stay","CIILOS - Continuous Renal Replacement Therapy, Impact on Intensive Care Unit Length of Stay","CIILOS","Inclusion Criteria:\n\n* Patients with critical illness\n* Admitted to Swedish ICUs from 2010-2023\n* Adult (18 years or older)\n\nExclusion Criteria:\n\n\\*Patients under 18 years of age",{"count":120,"type":21},500000,"OBSERVATIONAL","This large national cohort study, including over 500,000 patients, where around 5% are treated with continuous renal replacement therapy (CRRT) , aims to evaluate the association between time to initiation of CRRT and intensive care unit (ICU) length of stay (LOS).",[27,124],"Critical Illness",[29,126,127,124,128],"CRRT","CKRT","Intensive care","2026-05-18",{"date":131,"type":36},"2026-05-20",{"date":70,"type":21},{"date":134,"type":21},"2026-12-31",{"name":136,"class":43},"Karolinska Institutet",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100640735","personalized-two-stage-regional-citrate-anticoagulation-for-crrt-in-patients-with-citrate-metabolism-impairment-100640735","NCT07579663","Personalized Two-stage Regional Citrate Anticoagulation for CRRT in Patients With Citrate Metabolism Impairment","Personalized Two-stage Regional Citrate Anticoagulation for CRRT in Patients With Citrate Metabolism Impairment: a Multicenter Randomized Controlled Study","PRECISE","Inclusion Criteria:\n\nA. Aged 18 to 80 years, inclusive, male or female; B. Diagnosed with acute kidney injury or chronic kidney disease stage 5, and assessed by a physician as requiring continuous renal replacement therapy (CRRT); C. Citrate metabolism disorder, including liver failure (acute liver failure, acute-on-chronic liver failure, or decompensated cirrhosis), and\u002For microcirculation disorder (mean arterial pressure \\\u003C65 mmHg requiring vasopressor therapy and lactate ≥2 mmol\u002FL); D. The investigator determines that the patient can have a stable vascular access established (the access must be capable of providing a constant and effective blood flow rate \\>150 ml\u002Fmin); E. The study participant (subject) and their legal guardian are able to understand the study purpose and provide written informed consent.\n\nExclusion Criteria:\n\nA. Received regional citrate anticoagulation therapy within the previous 72 hours; B. Expected to require additional non-protocol calcium supplementation during CRRT due to disease-related needs; C. Requiring arterial-venous reversal of the extracorporeal circuit during CRRT due to poor flow; D. Requiring concurrent peritoneal dialysis during the trial period; E. Participated in or is currently participating in another clinical trial within 1 month prior to the date of signing the informed consent form; F. Expected survival time less than 72 hours; G. Any other conditions that, in the investigator's judgment, make the patient unsuitable for participation in the clinical trial.","80 Years",{"count":147,"type":21},142,[56],"The purpose of this study is to compare the efficacy and safety of an individualized two-stage calcium supplementation method versus a conventional commercial RCA-CRRT module in RCA-CRRT for patients with citrate metabolism disorders.",[27,151,152],"CKD 5D, Hemodialysis","Hepatic Failure",[154,155],"Regional Citrate Anticoagulation (RCA)","Continuous Renal Replacement Therapy (CRRT)","2026-05-05",{"date":158,"type":36},"2026-05-12",{"date":156,"type":21},{"date":161,"type":21},"2028-08-14",{"name":163,"class":43},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":182,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":4},"100619553","fluid-balance-guided-by-modified-venous-excess-ultrasonography-versus-standard-care-in-patients-with-acute-kidney-injury-receiving-continuous-renal-replacement-therapy-100619553","NCT07346118","Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy","Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy: A Multicentre Randomised Controlled Trial","mVExUS-CRRT","Inclusion Criteria:\n\n* Adults (≥ 18 years of age)\n* Admitted to ICU\n* Acute kidney injury by KDIGO criteria\n* Initiated CRRT by at least one of the following indications for RRT initiation:\n* Serum potassium ≥ 6.0 mmol\u002FL, or\n* pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol\u002FL, or\n* Evidence of severe respiratory failure, based on a PaO2\u002FFiO2 ≤ 200 and clinical perception of volume overload, or\n* Persistent severe AKI (sCr remains \\> 50% the value recorded at randomization) for \\> 72 hours from randomization\n* Participants giving informed consent\n\nExclusion Criteria:\n\n* Refuse to participate\n* Previous diagnosis of end-stage kidney disease (ESKD) currently on kidney replacement therapy\n* Kidney transplant recipient\n* Receive RRT before ICU admission within 90 days\n* Structural kidney diseases which will interfere with intrarenal doppler ultrasound e.g. renal artery stenosis, autosomal dominant polycystic kidney disease\n* Patients with previously known conditions that interfere with portal doppler assessment, namely liver cirrhosis, severe tricuspid regurgitation with structural heart disease or massive ascites.\n* Underlying disease process with a life expectancy less than 90 days\n* Pregnancy\n* Severe cardiac rhythm disturbances (tachyarrhythmia, supraventricular tachycardia)\n* Intra-cardiac shunts; Ventricle septal defect, patent foramen ovale, atrial septal defect\n* Aortic aneurysm\n* Intra-abdominal hypertension (intraabdominal pressure ≥20 mmHg)\n* Expected life expectancy \\\u003C48 hours\n* Receiving extracorporeal membrane oxygenation (ECMO)",{"count":173,"type":21},126,[56],"The goal of this randomised controlled trial is to compare the cumulative fluid balance over the first 72 h following inclusion guided by mVExUS versus standard of care in critically ill patients with acute kidney injury receiving CRKT . It will also compare the proportion of CRRT-related complications-including intradialytic hypotension and arrhythmias-between patients managed with mVExUS-guided fluid management and those receiving standard care.\n\nThe main questions it aims to answer are:\n\nDoes fluid removal rate guided by mVExUS will reduce cumulative fluid balance over the course of the first 72 h of CRRT in ICU patients compared to standard care\n\nParticipants will:\n\nGet fluid assessment by mVExUS protocol or a strandard care every 8 hours for 72 hours",[27,177,178,155,179,180,181],"Fluid Balance","Acute Circulatory Failure","VExUS","Passive Leg Raising","Biomarkers \u002F Blood",[95,183,184,185,186,187,188,189],"Fluid balance","Acute circulatory failure","Continuous kidney replacement therapy","mVExUS","Modified Venous Excess Ultrasound","Passive leg raising","Biomarker",{"date":191,"type":36},"2026-05-07",{"date":193,"type":21},"2026-07-01",{"date":195,"type":21},"2029-05-01",{"name":197,"class":43},"Chulalongkorn University",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":216,"leadSponsor":218,"locationsCount":44},"100601104","outpatient-recovery-from-acute-kidney-injury-requiring-dialysis---2-100601104","NCT07106151","Outpatient Recovery From Acute Kidney Injury Requiring Dialysis - 2","ORKID-2","Inclusion Criteria:\n\n* AKI-D (not ESKD, as determined by the clinical inpatient nephrology team)\n* Age ≥ 18 years\n* Planned for continued dialysis outside the acute hospital setting (at outpatient dialysis unit\u002FSNF\u002FLTACH, not planned transfer to another short-stay acute care hospital).\n\nExclusion Criteria:\n\n* Pregnant\n* Prisoner\n* Unable to consent and no surrogate decision maker available\n* Clinical team declines to allow approach for study",{"count":206,"type":21},40,[56],"Providing additional information to patients with acute kidney injury who continue dialysis after hospital discharge and to the accepting kidney doctor (nephrologist) who manages their dialysis may be feasible and beneficial. This study will pilot measuring the patient's residual kidney function at the time of discharge and communicating that result to the accepting nephrologist and the patient, along with information on recommended recovery monitoring frequency and criteria for consideration of a twice-weekly hemodialysis schedule.",[29,27,210],"Dialysis Patients","RECRUITING","2026-02-23",{"date":214,"type":36},"2026-02-27",{"date":212,"type":36},{"date":217,"type":21},"2028-01",{"name":219,"class":43},"University of California, San Francisco",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":233,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":44},"100616061","renal-histopathology-and-transcriptomic-analysis-in-hepatorenal-syndrome-during-liver-transplantation-100616061","NCT07300709","Renal Histopathology and Transcriptomic Analysis in Hepatorenal Syndrome During Liver Transplantation","Inclusion Criteria:\n\n1. Patient must be able to understand and provide informed consent\n2. Age ≥ 18 years of age at time of study entry\n3. Accepted for liver transplantation (LT)\n4. Fulfill the diagnostic criteria of HRS AKI according to International Club of Ascites (ICA) guidelines\n\n3-month post transplant renal biopsy inclusion criteria:\n\n1. Patient with adequate intraoperative renal biopsy\n2. Patient must be able to understand and provide informed consent\n\nExclusion Criteria:\n\n1. Inability or unwillingness to give written informed consent\n2. Patient with known pre-existing renal disease\n3. Patient with solitary kidney\n4. Re-transplantation\n5. ABO-incompatible LT\n6. Fail to provide 3-month post transplant renal biopsy\n\n3-month post transplant renal biopsy exclusion criteria:\n\n1. Graft failure after LT\n2. Any condition deemed inappropriate by the PI",{"count":227,"type":21},42,[56],"Hepatorenal Syndrome (HRS) is a serious complication that can occur in patients with liver cirrhosis, characterised by kidney dysfunction, or acute kidney failure (AKI). While it has traditionally been thought that HRS affects structurally normal kidneys and is completely reversible with liver transplantation, recent evidence suggests this may not always be the case.\n\nThe purpose of this study is to examine the actual structural changes in the kidneys of patients with HRS through tissue biopsy and advanced molecular analysis. This may help us better understand the disease mechanism and potentially improve treatment approaches. We aim to challenge the current understanding that HRS always occurs in structurally normal kidneys and is always reversible after liver transplantation. This study will provide valuable insights into the pathophysiology of HRS and may lead to improved diagnostic and treatment strategies in the future.\n\nThis is a 3-year single center prospective, non-randomised, open label study at Queen Mary Hospital, The University of Hong Kong. All consecutive patients accepted on the liver transplant waiting list will be invited to participate. Patient will undergo several procedures related to liver transplant and kidney assessment, and receive liver transplantation and renal biopsy.",[231,27,232],"Hepatorenal Syndrome, Liver Regeneration","Liver Transplant",[234,235,236,237,238,239,240,241],"Hepatorenal syndrome","HRS","HRS AKI","acute kidney injury","liver transplant","renal biopsy","renal histopathology","transcriptomics","2025-12-17",{"date":244,"type":36},"2025-12-24",{"date":246,"type":21},"2026-01-01",{"date":248,"type":21},"2028-12",{"name":250,"class":43},"The University of Hong Kong",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":4},"100613767","phase-4-study-to-evaluate-the-efficacy-of-intravenous-administration-of-human-albumin-versus-saline-solution-in-patients-with-descompnsate-cirrhosis-grade-1b-or-higher-renal-failure-100613767","NCT07270874","Study to Evaluate the Efficacy of Intravenous Administration of Human Albumin Versus Saline Solution in Patients With descompénsate Cirrhosis Grade 1B or Higher Renal Failure","LIVER AKI: A Randomized, Open-label Trial to Evaluate the Efficacy of Intravenous Human Albumin Administration Versus Saline Solution (NaCl 0.9%) in Patients With descompénsate Cirrhosis and AKI 1B or Grater","LIVER-AKI","Inclusion Criteria:\n\n1. Age ≥ 18 years old.\n2. Cirrhosis defined by standard clinical criteria, ultrasonographic findings and\u002For histology. (Cirrhosis of any etiology may be included).\n3. Patients with AKI 1B or greater, defined according to EASL guidelines (EASL. J Hepatol 2018).\n4. Women of child-bearing potential\\* must have a negative pregnancy test in serum before the inclusion in the study and agree to use highly effective contraceptive methods during the study. Highly effective contraceptive methods will include: intrauterine device, bilateral tubal occlusion, vasectomized partner and sexual abstinence\\*\\* (only if refraining from heterosexual intercourse during the period of twelve months). Hormonal contraceptive methods will be avoided due to the risk of adverse events and impairment of liver function\n\nExclusion Criteria:\n\n1. Time since AKI diagnosis \\> 24 hours.\n2. Patients with AKI due to pure hypovolemia. According to guidelines, these patients should receive crystalloid solutions (i.e. NaCl 0.9%) and will be excluded from the study. Fluid losses will be specifically assessed by an accurate anamnesis and physical examination. If patient's diuretic treatment has been increased recently (within prior 2 weeks), or the patient had diarrhea before admission, patient will be considered that the AKI phenotype is pre-renal and will be excluded from the analysis. Patients will be excluded when clear evidence of hypovolemia is present, based on clinical history (e.g, recent fluid losses, diuretic escalation, diarrhea) and corroborating physical findings (e.g, dry mucous membranes, reduced skin turgor, sunken eyes, or low jugular venous pressure)\n3. Patients with AKI due to gastrointestinal bleeding with AKI 1B or greater, and hemoglobin \\\u003C 7.0 g\u002FdL. These patients can be included after 48 hours without rebleeding and Hb ≥ 8.0 g\u002FdL, and still present AKI 1B or greater.\n4. Patients who had already received albumin at the time of inclusion\u002Fexclusion criteria assessment.\n5. Patients with Chronic kidney disease grade 3a or higher, defined as glomerular filtration rate \\\u003C60ml\u002Fmin for three months and markers of kidney damage (one or more): Albuminuria (Albumin excretion rate \\> 30 mg\u002F24h; Albumin-to-creatinine ratio \\> 30 mg\u002Fg), Urine sediment abnormalities, Electrolyte and other abnormalities due to tubular disorders, Abnormalities detected by histology or Structural abnormalities detected by imaging.\n6. Patients under renal replacement therapy, or with urgent criteria of RRT.\n7. Patients with hepatocellular carcinoma beyond Milan criteria.\n8. Patients with severe extrahepatic comorbidities, including congestive heart failure New York Heart Association Grade III\u002FIV, chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease group 2 or higher.\n9. Previous liver and\u002For kidney transplantation.\n10. Patients with current extra hepatic malignancies including solid tumors and hematologic disorders.\n11. Patients included in other clinical trials in the month before inclusion.\n12. Patients with mental incapacity, language barrier, bad social support or any other reason considered by the investigator precluding adequate understanding, cooperation or compliance in the study.\n13. Refusal to give informed consent.",{"count":260,"type":21},114,[86],"This is a phase IV, unicentric, open-label. Patients eligible for this study will be patients with AKI 1B or greater and decompensated cirrhosis from the hospital participating in the study",[264,27],"Decompensated Cirrhosis","2025-12-16",{"date":267,"type":36},"2025-12-18",{"date":269,"type":21},"2026-01",{"date":271,"type":21},"2028-02",{"name":273,"class":43},"Fundacion Clinic per a la Recerca Biomédica",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":281,"targetDuration":283,"studyType":121,"phases":4,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":44},"100615611","contrast-enhanced-ultrasound-and-super-resolution-imaging-predict-renal-function-outcome-after-nephrectomy-100615611","NCT07294859","Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy","A Prospective Clinical Study on the Predictive Value of CEUS and Super-resolution Imaging Technology for Renal Function Outcome in Patients After Partial or Radical Nephrectomy","Inclusion Criteria:\n\n* Fully understood and voluntarily signed the informed Consent Form (ICF);\n* Age: \\> 18 (at the time of signing the informed consent form); Gender is not limited.\n* Preoperative eGFR \\> 45ml\u002Fmin\u002F1.73m2 (corrected CKD-EPI formula);\n* After the clinician formulates the treatment plan and communicates with the patient, they decide whether to perform radical nephrectomy or partial nephrectomy.\n* ECOG score: 0-2 points;\n* Be willing and able to abide by the visits, treatments, laboratory tests and other procedures of the research plan.\n\nExclusion Criteria:\n\n* Patients with solitary kidney or severe contralateral renal insufficiency (eGFR \\\u003C 15ml\u002Fmin\u002F1.73m2);\n* Preoperative reliance on renal replacement therapy (such as dialysis, etc.);\n* Those who fail to complete the nephrectomy as planned during the operation;\n* Patients with lymph node metastasis, distant metastasis or venous tumor thrombus;\n* The healthy kidney has undergone radiotherapy, ablation or other surgeries.\n* Have a history of allergy to ultrasound contrast agents;\n* Have any contraindications for contrast-enhanced ultrasound, such as right-to-left shunt, severe pulmonary hypertension, etc.\n* Patients with hemodynamic instability, including those with persistent hypotension (blood pressure \\\u003C 90\u002F60 MMHG), uncontrollable heart failure, active bleeding (such as gastrointestinal and cerebral hemorrhage, etc.), or those with a bleeding tendency and hemoglobin \\\u003C 60g\u002FL and\u002For platelet count \\\u003C 50×109\u002FL;\n* Accompanied by structural abnormalities of the urinary system or functional abnormalities that cannot be corrected in a short time (such as duplicate kidneys, polycystic kidneys, horseshoe kidneys, isolated kidneys, renal artery stenosis \\> 50%, urinary tract obstruction, and previous history of kidney surgery, etc.), long-term indwelling of urinary catheters, etc.\n* There are other diseases that limit life expectancy to less than six months;\n* Previous (≤30 days before randomization) or concurrent participation in another clinical study.",{"count":282,"type":21},285,"12 Months","The goal of this prospective cohort study is to evaluate the predictive value of Contrast-Enhanced Ultrasound (CEUS) and Super-Resolution Imaging (SRI) technologies regarding renal function outcomes in patients with renal cell carcinoma (RCC) undergoing partial or radical nephrectomy. The main questions it aims to answer are:\n\nCan quantitative parameters of renal microcirculation and microvascular structure derived from CEUS and SRI predict long-term renal function (defined as New Baseline eGFR for radical nephrectomy and Recovery from Ischemia for partial nephrectomy)? Can these imaging parameters accurately predict the occurrence, severity, and early recovery of postoperative acute kidney injury (AKI)? Researchers will monitor the dynamic evolution of renal blood flow and microvascular density by comparing the affected kidney to the contralateral healthy kidney before and after surgery to see if these biomarkers correlate with clinical outcomes.\n\nParticipants will:\n\nUndergo CEUS and SRI examinations before surgery and at specific time points after surgery (e.g., within 7 days) to visualize renal microvasculature.\n\nProvide blood and urine samples for standard laboratory tests (such as serum creatinine and Cystatin C) to assess kidney function during hospitalization.\n\nAttend follow-up visits at 1, 3, 6, 9, and 12 months post-surgery to monitor long-term renal recovery and complete necessary imaging assessments (CT or Ultrasound).",[286,287,27],"Nephrectomy","Renal Cell Cancer","2025-12-08",{"date":290,"type":36},"2025-12-19",{"date":292,"type":36},"2025-09-01",{"date":294,"type":21},"2027-12-01",{"name":296,"class":43},"Jinling Hospital, China",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":306,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":316,"locationsCount":44},"100549953","to-compare-the-efficacy-and-safety-of-using-oxiris-and-m100-during-crrt-100549953","NCT06440759","To Compare the Efficacy and Safety of Using oXiris and M100 During CRRT","Evaluation of Efficacy and Safety Using oXiris Versus M100 Filter in Pneumonia-induced Acute Kidney Injury (AKI) Patients Requiring Continuous Renal Replacement Therapy (CRRT)","Inclusion Criteria:\n\n* All adult patients aged\\>18 years old\n* Diagnosis of septic shock\n* Diagnosis of KDIGO stage 3 acute renal failure\n\nExclusion Criteria:\n\n* Moribund patient or patient that is expected to die within 72 hours\n* Pregnancy\n* patient with a bleeding tendency or known allergy to heparin",{"count":305,"type":21},60,[56],"The purpose of this study aimed to compare the efficacy of Oxiris (Baxter) and M100 filters on IL-6 as primary outcomes and other blood cell counts, blood biochemistry (serum urea, creatinine, potassium, sodium), inflammation indicators (CRP, PCT), as secondary outcomes and safety (28 days mortality as a primary outcome and coagulopathy, lifespan of filter, usage of vasopressor, clinical conditions (ventilator-free days, ICU and hospital- length of stay) as a secondary outcome), clinical conditions (ventilator-free days, ICU and hospital- length of stay), and mortality of patients with pneumonia-related AKI.",[27,309],"Pneumonia","2025-09-30",{"date":312,"type":36},"2025-10-02",{"date":314,"type":36},"2024-05-30",{"date":105,"type":21},{"name":317,"class":43},"Mohd Zulfakar Mazlan, MBBS",{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":22,"phases":328,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":44},"100603144","the-efficacy-of-intravenous-amino-acids-in-reducing-the-occurrence-of-aki-after-live-donor-liver-transplant-100603144","NCT07132697","The Efficacy of Intravenous Amino Acids in Reducing the Occurrence of AKI After Live Donor Liver Transplant","The Efficacy of Intravenous Amino Acids in Reducing the Occurrence of AKI After Live Donor Liver Transplant: An Open Label Randomized Trial","Inclusion Criteria\n\n1. All LDLT Recipient\n2. Age: \\> 18 years\n3. Signed informed consent\n\nExclusion Criteria\n\n1. Negative consent.\n2. Pediatric LDLT.\n3. ALF patient undergoing LDLT.\n4. Patients on intermittent or continuous renal replacement therapy.\n5. Patients with eGFR less then 40 ml per min per 1.73 m2.\n6. SLKT and prior Kidney transplant.\n7. Patient has a hypersensitivity (known allergy) to one or more of the included amino acids.\n8. Patient has a known congenital alteration of amino acid metabolism.","70 Years",{"count":327,"type":21},100,[56],"This prospective, open-label, randomized controlled trial aims to evaluate the efficacy of intravenous amino acid infusion in reducing AKI after LDLT. Eligible adult patients undergoing LDLT will be randomized into two groups: one receiving Continuous infusion of a L-amino acids mixture in a dose of 2 g\u002Fkg dry body weight\u002Fday (to a maximum 100 g\u002Fday) after induction of anesthesia and insertion of CVP line till 72 hours after treatment initiation, and the other receiving standard management. The primary outcome is the incidence of AKI as per KDIGO criteria within 7 days of transplant.",[331,27],"Liver Transplant; Complications",[333],"Liver Transplantation, Acute Kidney Injury, Amino Acids, KDIGO, NGAL, Randomized Controlled Trial","2025-08-13",{"date":336,"type":36},"2025-08-20",{"date":338,"type":21},"2025-08-25",{"date":340,"type":21},"2026-09-01",{"name":342,"class":43},"Institute of Liver and Biliary Sciences, India",{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":22,"phases":353,"briefSummary":354,"conditions":355,"keywords":357,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":364,"leadSponsor":366,"locationsCount":369},"100602471","safety--efficacy-of-renalguard-therapy-in-the-prevention-of-cardiac-surgery-associated-acute-kidney-injury-100602471","NCT07123935","Safety & Efficacy of RenalGuard® Therapy in the Prevention of Cardiac Surgery Associated Acute Kidney Injury","Assessing the Safety & Efficacy of RenalGuard® Therapy in the Prevention of Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) - SAFEGUARD Study","SAFEGUARD","Inclusion Criteria:\n\n1. Male or female and \\>18 years old.\n2. Patient able to give written consent.\n3. Scheduled for the following non-emergent cardiac surgery procedure requiring CPB, isolated or in combination:\n\n   * coronary artery bypass graft (CABG)\n   * aortic valve replacement or repair alone, with or without aortic root repair\n   * mitral, tricuspid, or pulmonic valve replacement or repair\n   * simultaneous replacement of several cardiac valves\n   * CABG with aortic, mitral, tricuspid, or pulmonic valve replacement or repair\n   * Surgery on the aorta: aortic root and\u002F or ascending aorta\n   * AF ablation surgery if combined with other cardiac procedures.\n   * ASD closure if combined with other cardiac procedures.\n   * Excision of myxoma if combined with other cardiac procedures\n4. Have at least one of the following risk factors for CSA-AKI:\n\n   * CKD-EPI eGFR 20-59 mL\u002Fmin\u002F1.73 m²\n   * Undergoing combined surgery (e.g. CABG + Valve)\n   * STS Score ≥4 or Logistic EuroScore of ≥5 or, Euroscore II of ≥4\n   * Left ventricular ejection fraction (LVEF) ≤ 35%\n   * Insulin-requiring diabetes\n   * Non-insulin-requiring diabetes with HbA1C ≥ 6.1% in the last 6 months\n   * Preoperative anemia (hemoglobin ≤11g\u002Fdl for men and women) within 4 weeks of surgery\n\nExclusion Criteria:\n\n1. Patient requiring emergency surgery\n2. Surgery to be performed without CPB\n3. Patient receiving furosemide at a dose\\>100 mg\u002Fday orally (or the equivalent dose of an alternative loop diuretic) in the last week\n4. Patient who cannot be urethrally catheterize for any reason\n5. Patients already dialysis dependent\n6. Patients with CKD-EPI eGFR \\\u003C20 mL\u002Fmin\u002F1.73 m²\n7. Known or suspected AKI (KDIGO criteria) at the time of screening\n8. IV contrast within 48 hours of surgery\n9. Patients participating in another interventional drug or device study or have received an investigational drug or device treatment within the last 30 days\n10. Pregnant patient, self-reported\n11. Patients whose planned surgery to be performed under conditions of circulatory arrest or hypothermia with rectal temperature \\\u003C 28°Celsius (82.4° Fahrenheit)\n12. Patient with suspected or confirmed bacteraemia, endocarditis, or pyelonephritis at hospital admission\n13. Patients with pneumonia, aspiration, or bilateral pulmonary infiltrates from an infectious aetiology reported on chest x-ray or CT scan in the last 7 days\n14. Patients in cardiogenic shock or hemodynamic instability which require inotropes or vasopressors or other mechanical devices (Impella, IABP) within 24 hours prior to surgery\n15. Patients on extracorporeal membrane oxygenation (ECMO) or durable ventricular assist device (VAD) at the time of screening, or planned use within 24h prior to surgery\n16. Patients currently treated with chemotherapy or radiation therapy that may have an impact on kidney function.\n17. Patient underwent prior solid organ transplantation\n18. Patients underwent major surgery within the last 3 months\n19. Any condition which, in the judgement of the investigator, might increase the risk to the patient",{"count":352,"type":21},300,[56],"The goal of this clinical trial is to assess the effect of RenalGuard Therapy in reducing the rates of Acute Kidney Injury (AKI) within 72 hours after cardiac surgery in patients at risk of developing Cardiac Surgery Associated AKI (CSA-AKI) compared to standard-of-care (SoC).\n\nThe study is planned to be conducted in 2 clinical sites in the Malaysia - Universiti Malaya Medical Centre and Institut Jantung Negara, Kuala Lumpur, Malaysia.\n\nParticipants will be randomized (1:1) to one of the two study groups. The Treatment study group will be managed with the RenalGuard System. The RenalGuard treatment will start after induction of anesthesiology and will run during surgery and for 6-7 hours in the Intensive Care Unit (ICU). The treatment will aim to achieve a urine rate above a predefined urine rate threshold. Patients in the control group will be managed based on the usual clinical practice in cardiac surgery centres as detailed in the recommendations for CSA-AKI prevention by accepted clinical guidelines.\n\nFor both study groups general anaesthesia, cardiopulmonary bypass (CPB) run and overall patient care will be based on SoC for cardiac surgery.\n\nPatients will be followed up for up to 7 days post surgery or until discharge, which ever comes first.\n\nLong-term follow up will be performed at 90 days post surgery.",[356,27],"Cardiac Surgery Associated - Acute Kidney Injury",[237,30,358,359],"RenalGuard Therapy","matched enhanced diuresis","2025-08-12",{"date":362,"type":36},"2025-08-14",{"date":292,"type":21},{"date":365,"type":21},"2027-06-30",{"name":367,"class":368},"CardioRenal Systems, Inc.","INDUSTRY",2,{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":376,"targetDuration":377,"studyType":121,"phases":4,"briefSummary":378,"conditions":379,"keywords":382,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":44},"100570331","a-comparison-of-renal-vs-limb-nirs-for-predicting-cardiac-surgery-associated-acute-kidney-injury-100570331","NCT06705855","A Comparison of Renal vs Limb NIRS for Predicting Cardiac Surgery Associated Acute Kidney Injury","Inclusion Criteria:\n\n* We will enroll a convenience sample of adult cardiac surgery patients undergoing procedures that require cardiopulmonary bypass (CPB) and who are at risk for AKI.\n\nExclusion Criteria:\n\n* Exclusion criteria will include less than age 18 years old, preoperative end-stage kidney disease requiring dialysis, emergency surgery, or patient refusal.",{"count":327,"type":21},"30 Days","Acute kidney injury (AKI) is a complication of cardiac surgery that can affect outcome. Near Infrared Spectroscopy (NIRS) is a technology that uses light to determine how well oxygenated tissues are. This technology is routinely used in cardiac surgery to measure the oxygen level in the brain by placing a sensor sticker on the forehead. The purpose of the study is to determine whether NIRS sensor stickers placed on the skin over the kidney can predict AKI better than when sensors are placed on the skin over the participant's limbs. This study is being conducted by investigators from the department of anesthesiology at the University of Utah.",[380,356,381,27],"NIRS","Cardiac Surgery Requiring Cardiopulmonary Bypass",[383],"Cardiovascular",{"date":385,"type":36},"2025-08-17",{"date":387,"type":36},"2025-05-29",{"date":389,"type":21},"2026-08-30",{"name":391,"class":43},"University of Utah",{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":400,"targetDuration":402,"studyType":121,"phases":4,"briefSummary":403,"conditions":404,"keywords":406,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":417,"leadSponsor":418,"locationsCount":4},"100599499","perfusion-related-evaluation-of-systemic-and-renal-vulnerability-to-events-in-cabg-100599499","NCT07085286","Perfusion Related Evaluation of Systemic and Renal Vulnerability to Events in CABG","Prognostic Value of Continuous Intra-abdominal Pressure (CIAP) and Continuous Abdominal Perfusion Pressure (CAPP) Monitoring for Acute Kidney Injury (AKI) Prediuction in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery","PRESERVE-CABG","Inclusion Criteria\n\n* Age 18 years or older\n* Undergoing cardiac surgery (CABG, valve surgery, combined procedures, heart transplantation, or placement of assist device)\n* Expected hospital stay of at least one night\n* Preoperative serum creatinine measurement available\n* At least one postoperative serum creatinine measurement available\n\nExclusion Criteria\n\n* Age below 18 years\n* Incarcerated individuals\n* No requirement for urinary catheter placement\n* Presence of a do-not-resuscitate (DNR) order\n* Pregnant or lactating individuals\n* Fewer than 12 hours of recorded data (including intraoperative data)\n* No informed consent (if a waiver is not granted)\n* Pre-existing chronic kidney disease, defined as estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m²",{"count":401,"type":21},45,"6 Months","The goal of this observational study is to learn whether high abdominal pressure or low blood flow pressure to the kidneys is linked to kidney injury after heart surgery. The main questions it aims to answer are:\n\nDoes high abdominal pressure increase the risk of kidney injury after cardiac surgery?\n\nCan low blood flow pressure to the kidneys help predict who may develop kidney problems?\n\nParticipants in this study are adults undergoing heart surgery, such as coronary artery bypass grafting (CABG) or valve surgery. Researchers will measure abdominal pressure and blood pressure continuously before and after surgery using medical devices that are already part of routine care. This study does not involve any changes to standard treatment.\n\nParticipants will:\n\nHave their abdominal and blood pressures continuously monitored using existing devices\n\nHave blood and urine tests to check kidney function\n\nBe followed during their hospital stay and up to 30 days after surgery to assess outcomes like length of stay, readmission, and survival\n\nThis study takes place at two hospitals-one in Poland and one in the United States. Researchers hope the findings will help identify early warning signs of kidney injury and improve monitoring practices after heart surgery.",[27,405],"CABG",[407,408,409,410,411,412,29],"abdominal pressure","IAP","abdominal perfusion pressure","mean perfusion pressure","renal perfusion pressure","prediction","2025-07-17",{"date":415,"type":36},"2025-07-25",{"date":246,"type":21},{"date":134,"type":21},{"name":419,"class":43},"Medical University of Lublin",{"id":421,"slug":422,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":428,"conditions":429,"keywords":434,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":44},"100594658","urine-output-response-to-fluid-and-diuretic-therapy-in-cardiac-icu-patients-monitored-with-fize-kuo-100594658","NCT07022314","Urine Output Response to Fluid and Diuretic Therapy in Cardiac ICU Patients Monitored With FIZE kUO®","FIZE kUO® Real-Time Measurement of Urine Output Response to Fluid Therapy and Diuretics in Cardiovascular Surgery Patients: A Prospective Post-Market Study","Inclusion Criteria:\n\n1. Adults aged 18 years and older scheduled for CABG or valve surgery and expected postoperative admission to CTICU\n2. Ability to provide informed consent\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Preoperative dialysis (chronic or acute)\n3. Enrollment in other interventional trials assessing urine output or AKI",{"count":401,"type":21},"This prospective observational study evaluates the real-time urine output response to fluid therapy and diuretics in cardiothoracic intensive care unit (CTICU) patients monitored with the FIZE kUO® device. The study aims to assess how continuous urine output monitoring can inform fluid management and improve patient outcomes post-cardiac surgery.",[27,430,431,432,433],"Cardiac Surgery","Fluid Therapy","Hemodynamic Instability","Postoperative Complications",[435,436,437,438,439],"FIZE kUO","Urine Output","Fluid Management","Diuretics","Cardiothoracic Surgery","2025-06-12",{"date":442,"type":36},"2025-06-15",{"date":444,"type":21},"2025-07",{"date":446,"type":21},"2026-06",{"name":448,"class":368},"FIZE Medical ltd",{"id":450,"slug":451,"hasResults":11,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":456,"enrollmentInfo":457,"targetDuration":4,"studyType":22,"phases":459,"briefSummary":461,"conditions":462,"keywords":463,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":44},"100586629","phase-1-prophylactic-methylprednisolone-for-renal-protection-in-cardiac-surgeries-with-cardiopulmonary-bypass-100586629","NCT06917859","Prophylactic Methylprednisolone for Renal Protection in Cardiac Surgeries With Cardiopulmonary Bypass","Prophylactic Methylprednisolone for Renal Protection in Cardiac Surgeries With Cardiopulmonary Bypass: A Randomized Double-Blinded Clinical Study","Inclusion Criteria:\n\n1. Age 18-65 years.\n2. Sex: Both sexes.\n3. Patients with American Society of Anesthesiologists (ASA) score III-IV.\n4. Patients scheduled for any kind of elective cardiac surgical procedure requiring cardiopulmonary bypass (e.g., coronary artery bypass grafting (CABG), valve repair\u002Freplacement, or combined procedures (\n\nExclusion Criteria:\n\n1. Declining to give written informed consent.\n2. History of allergy to the medications used in the study.\n3. Diabetic patients with HbA1C \\>6.5\n4. Moderate to severe hepatic diseases (Child B-C)\n5. Hepatic dysfunction: INR \\> 1.5, serum albumin \\\u003C 2.9 g%.\n6. Renal dysfunction (serum Creatinine level \\>1.3 mg\u002Fdl, or GFR \\\u003C 80 ml\u002Fmin.\u002F1.73\u002Fm2\n7. Patients with a recent history of AKI.\n8. Patients undergoing urgent cardiac surgery.\n9. Patients undergoing cardiac surgeries with deep hypothermic total circulatory arrest.\n10. Planned off-pump procedure.\n11. Any cardiac surgery exceeds 45 minutes on Aortic cross clamp.\n12. Patients requiring high doses of inotropes and\u002For vasopressors intraoperative or postoperative (high-dose dopamine is defined as peak doses of \\>15 μg\u002Fkg\u002Fmin, high-dose norepinephrine is defined as peak dose \\>0.1 μg\u002Fkg\u002Fmin, high-dose epinephrine is defined as peak dose \\>0.1 μg\u002Fkg\u002Fmin)\n13. Delayed extubation for more than 6 hours postoperative.\n14. Patients developed postoperative complications as (septic shock and bleeding)","65 Years",{"count":458,"type":21},170,[460],"PHASE1","The aim of the planned study is to assess the prophylactic effect of intraoperative administration of a single dose of methylprednisolone 2 (mg\u002Fkg) in decreasing the incidence of postoperative acute kidney injury after cardiac surgeries with cardiopulmonary bypass.",[90,27],[29,464],"CPB","2025-04-04",{"date":467,"type":36},"2025-04-09",{"date":469,"type":36},"2025-02-01",{"date":471,"type":21},"2026-12-01",{"name":473,"class":43},"Ain Shams University",{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":482,"conditions":483,"keywords":485,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":44},"100585928","efficacy-and-safety-of-citrate-anticoagulation-in-crrt-for-patients-with-liver-failuredysfunction-the-caution-trial-a-retrospective-study-on-etiology-of-liver-failure-and-their-complications-100585928","NCT06908746","Efficacy and Safety of Citrate Anticoagulation in CRRT for Patients With Liver Failure\u002FDysfuncTION, the CAUTION Trial! A Retrospective Study on Etiology of Liver Failure and Their Complications","Caution","Inclusion Criteria:\n\n* Critically ill patients diagnosed with AKI requiring CRRT. Caution Protocol V1.0 24-07-2024\n* Documented liver failure or significant liver dysfunction (e.g., elevated liver enzymes, bilirubin levels, or clinical diagnosis of liver failure) and clincal diagnosis of shock (NE of 0.25 μg\u002Fkg\u002Fmin and or association of second vasopressor).\n* Age ≥ 18 years.\n\nExclusion Criteria:\n\n* NA",{"count":327,"type":21},"Study design A retrospective cohort study will be conducted to compare the efficacy and safety of citrate anticoagulation in CRRT among patients with liver failure\u002Fdysfunction and severe shock.\n\nObjectives\n\n1. Primary Objective: To determine if the etiology of liver failure impacts the incidence of citrate-related complications in patients undergoing CRRT.\n2. Secondary Objectives: To compare the efficacy of citrate anticoagulation in terms of renal recovery, filter lifespan, and patient survival between those with liver failure\u002Fdysfunction and severe shock.",[484,27],"Liver Failure",[126,486,29],"liver failure","2025-04-02",{"date":489,"type":36},"2025-04-03",{"date":491,"type":36},"2024-09-30",{"date":493,"type":21},"2025-12-31",{"name":495,"class":43},"University Hospital, Antwerp",{"id":497,"slug":498,"hasResults":11,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":44},"100586567","renal-perfusion-and-the-development-of-aki-following-traumatic-injury-100586567","NCT06917053","Renal Perfusion and the Development of AKI Following Traumatic Injury","Renal Perfusion and the Development of AKI Following Traumatic Injury - A Longitudinal Observational Cohort Study","PERTAKI","Inclusion Criteria:\n\n* Age \\> 18 years\n* Within 24 hours of ICU admission following traumatic injury\n* Received any blood products during initial resuscitation\n* Lactate \\> 2 mmol\u002Fl at any stage prior to study enrolment\n\nExclusion Criteria:\n\n* Known intolerance to Sonovue or any other ultrasound contrast agent\n* Patients with un-survivable injuries \u002F not expected to survive 24 hours in whom the intent of treatment is palliative\n* Known CKD 4 or end stage renal failure\n* Pregnancy",{"count":505,"type":21},20,"Acute kidney injury (AKI) is a complication of traumatic haemorrhagic shock (THS) and together these conditions increase mortality risk. Although septic shock patients who develop severe AKI are known to develop hypoperfusion of the renal cortex, little is known regarding intra-renal perfusion changes in THS. The aim of the current study is to investigate the effects of THS on renal microcirculatory perfusion.",[508,509,27],"Traumatic Haemorrhagic Shock","AKI (Acute Kidney Injury) Due to Trauma","2025-04-01",{"date":512,"type":36},"2025-04-08",{"date":514,"type":36},"2024-04-13",{"date":516,"type":21},"2026-07",{"name":518,"class":43},"King's College Hospital NHS Trust",{"id":520,"slug":521,"hasResults":11,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":22,"phases":528,"briefSummary":529,"conditions":530,"keywords":531,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":540,"locationsCount":44},"100557886","pharmacokinetics-vancomycin-cvvhdf-with-oxiris-membrane-100557886","NCT06543940","Pharmacokinetics Vancomycin CVVHDF with OXiris Membrane","Pharmacokinetics of Vancomycin in Patients Receiving Continuous Veno-Venous Hemodiafiltration (CVVHDF) with the Absorptive OXiris Membrane","Inclusion Criteria:\n\n* Patients aged more than 18 years.\n* Admitted to the intensive care unit of Ramathibodi Hospital.\n* Under continuous renal replacement therapy (CRRT) with CVVHDF using oXiris filter.\n* Received vancomycin at least once after starting CRRT with CVVHDF using oXiris filter.\n* who have signed the informed consent document.\n\nExclusion Criteria:\n\n* Patients with a history of vancomycin allergy.\n* Patients expected to die within 24 hours after inclusion in study.\n* Patients with circuit clotting occurring more than 2 hours during the blood draw period.\n* Patients treated with extracorporeal membrane oxygenation (ECMO).\n* Patients with a history of kidney transplantation.\n* Pregnant or breastfeeding women.\n* Patients who have decided to receive palliative care.\n* Patients on hemodialysis or peritoneal dialysis.",{"count":527,"type":21},8,[56],"This study is a general pharmacokinetic investigation of vancomycin in patients receiving continuous veno-venous hemodiafiltration (CRRT) with the oXiris membrane. This membrane offers the added benefit of absorbing inflammatory cytokines. In vitro studies show that vancomycin is reduced by around 20 percent in patients using the AN69ST membrane, which is part of the oXiris membrane's structure. However, there is currently a lack of in vivo studies demonstrating the impact of the oXiris membrane on vancomycin levels. Therefore, the hypothesis of this study is that vancomycin is also reduced by absorption in the oXiris membrane. This study measures the levels of vancomycin in these patients to determine the pharmacokinetic parameters.",[27],[532,126,533],"vancomycin","oXiris membrane","2025-01-23",{"date":536,"type":36},"2025-01-24",{"date":538,"type":36},"2024-09-01",{"date":493,"type":21},{"name":541,"class":43},"Mahidol University",{"id":543,"slug":544,"hasResults":11,"nctId":545,"briefTitle":546,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":548,"sex":17,"minAge":18,"maxAge":549,"enrollmentInfo":550,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":4},"100524896","parameters-of-the-recovery-time-of-acute-kidney-injury-in-critically-ill-patients-100524896","NCT06114693","Parameters of the Recovery Time of Acute Kidney Injury in Critically Ill Patients","Inclusion Criteria:\n\n1:adult patients (age ≥ 18 years) who admitted to the ICU for at least 24 hours and experience AKI\n\nExclusion Criteria:\n\n1. patients (age \\\u003C18 years)\n2. Patient who refuse enter study Patient",true,"85 Years",{"count":551,"type":21},150,"the primary objective of this study is to identify and analyze parametrers affecting the time of recovery of AKI in critical ill patient ,Specifically, the study aims to:\n\n1. to identify outcomes of critically ill patients who experienced AKI\n2. Examine the relationship between demographic and clinical variables (e.g., age, gender, comorbidities) and outcome of AKI patient\n3. follow Baseline characteristics and laboratory findings of the patients at the time of admission to the intensive care unit and affecting it at recovery time\n4. Explore the association between psychosocial factors (e.g., depression, anxiety, social support) and outcome of AKI patient at icu",[27],"2025-01-09",{"date":556,"type":36},"2025-01-13",{"date":558,"type":21},"2025-01",{"date":560,"type":21},"2025-09",{"name":562,"class":43},"Assiut University",{"id":564,"slug":565,"hasResults":11,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":548,"sex":17,"minAge":570,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":573,"conditions":574,"keywords":4,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":44},"100544711","mechanisms-of-acute-kidney-injury-in-severe-infections-100544711","NCT06372444","Mechanisms of Acute Kidney Injury in Severe Infections","PET-AKI","Inclusion Criteria:\n\nPatients with sepsis and AKI\n\n* \\> 30 years\n* At least AKI stage 1 according to KDIGO where the last plasma creatinine is measured within 24 hours of the examination\n\nHealthy volunteers\n\n* \\> 30 years\n* No previously known kidney disease\n* Normal plasma creatinine value\n\nExclusion Criteria:\n\n* Chronic renal failure (CKD stage \\>3a) or dialysis\n* Instability in vital functions that makes PET-CT examination unsuitable\n* Claustrophobia or other reasons that make the patient unable to lie still during the examination.\n* Pregnancy and breastfeeding","30 Years",{"count":572,"type":21},15,"Renal perfusion and neutrophil-mediated inflammation will be assessed in the kidney in sepsis patients with acute kidney injury using positron emission tomography. For marked water will be used for renal perfusion and a newly developed PET tracer molecule (11C-GW457427) with specific binding to neutrophil elastase which provides a measure of the amount of infiltrating neutrophils in the renal parenchyma for inflammation. The study is performed in a PET-CT camera where anatomical imaging takes place at the same time as the PET examinations.",[575,27,576],"Sepsis","Positron Emission Tomography (PET)","2024-12-03",{"date":579,"type":36},"2024-12-06",{"date":581,"type":36},"2024-05-01",{"date":583,"type":21},"2026-06-30",{"name":585,"class":43},"Uppsala University Hospital",{"id":587,"slug":588,"hasResults":11,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":592,"eligibilityCriteria":593,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":22,"phases":596,"briefSummary":597,"conditions":598,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":44},"100554840","oxiris-for-abdominal-septic-shock-oases-study-100554840","NCT06504316","OXiris for Abdominal SEptic Shock (OASES Study)","A Multicenter, Randomized Control Clinical Trial on the Effect of Adsorptive Filter oXiris on Hemodynamics of Abdominal Septic Shock Patients","OASES","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Weight ≥30 kg;\n3. Intra-abdominal infection (blood or abdominal drainage fluid culture positive for Gram-negative bacteria or suspected to be caused by a Gram-negative agent);\n4. Diagnostic septic shock (Sepsis 3.0): Sepsis was defined as \"life-threatening organ dysfunction caused by a dysregulated host response to infection\" with organ dysfunction defined as an increase in qSOFA ⩾2 points. Septic shock was defined as sepsis requiring vasoactive therapy to maintain mean arterial pressure (MAP) ⩾ 65 mmHg and lactate elevation to \\>2 mmol\u002FL despite adequate volume resuscitation;\n5. The dose of norepinephrine⩾0.4ug\u002Fkg\u002Fmin;\n6. PCT⩾50ug\u002FL, and\u002For IL-6⩾1000pg\u002Fml;\n7. AKI stage II\u002FIII (Kidney Disease Improving Global Outcomes, KDIGO grade);\n8. Duration of septic shock ≤48 hours.\n\nExclusion Criteria:\n\n1. Patients with highly contagious infectious diseases, such as tuberculosis;\n2. Pregnant and lying-in woman or lactation period;\n3. Infection of other sites (no abdominal infection like pneumonia, central nervous system infection and so on);\n4. CRRT cannot be performed for various reasons;\n5. Death is expected within 48 hours of admission to the ICU;\n6. Previous renal replacement therapy;\n7. Patients that underwent cardio-pulmonary resuscitation (CPR);\n8. Patients who will not sign the informed consent form.",{"count":595,"type":21},192,[56],"This study innovatively utilizes multi-modal hemodynamic monitoring (Norepinephrine equivalence, NEE+Pulse indicator Continuous Cariac output, PiCCO) to investigate the optimal timing of initiation of oXiris in abdominal infection-associated septic shock patients and to investigate prognosis on sepsis phenotypes undergoing oXiris therapy.",[599,600,601,602,27],"Septic Shock","Abdominal Sepsis","Multi Organ Failure","Blood Purification","2024-07-10",{"date":605,"type":36},"2024-07-16",{"date":607,"type":21},"2024-08-15",{"date":609,"type":21},"2027-05-31",{"name":611,"class":43},"RenJi Hospital"]